DYN NASDAQ
Dyne Therapeutics, Inc.
1W: -5.0%
1M: -11.7%
3M: +16.7%
YTD: -6.1%
1Y: +40.8%
3Y: +30.1%
5Y: -0.6%
$17.37
+0.00 (+0.00%)
Weekly Expected Move ±7.8%
$15
$16
$17
$19
$20
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.9B
52W Range8.06-25
Volume1,405,056
Avg Volume2,018,911
Beta1.08
Dividend—
Analyst Ratings
Company Info
CEOJohn G. Cox
Employees192
SectorHealthcare
IndustryBiotechnology
IPO Date2020-09-17
Websitedyne-tx.com
1560 Trapelo Road
Waltham, MA 02451
US
Waltham, MA 02451
US
781 786 8230
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Latest News
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne spikes as late-stage trial for Duchenne therapy gets underway
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Posner Brian S | P-Purchase | 2,500 | $17.12 | 2026-05-20 |
| Friedl-Naderer Johan | S-Sale | 228 | $18.36 | 2026-05-13 |
| Kerr Douglas | S-Sale | 1,564 | $18.36 | 2026-05-13 |
| Lucera Erick | S-Sale | 1,448 | $18.36 | 2026-05-13 |
| Cox John | S-Sale | 3,311 | $18.36 | 2026-05-13 |